CCHT(000661)2024-04-19 08:25Financial Performance - The company's revenue for Q1 2024 reached ¥3,177,355,203.27, representing a 14.39% increase compared to ¥2,777,673,498.10 in the same period last year[5] - Net profit attributable to shareholders was ¥858,728,236.98, a slight increase of 0.20% from ¥856,993,773.27 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥846,699,463.31, showing a decrease of 0.86% compared to ¥854,005,319.18 in the previous year[5] - The company reported non-recurring gains of ¥12,028,773.67 for the period, which included government subsidies and other income[6] - The total comprehensive income for Q1 2024 was ¥889,346,936.00, compared to ¥852,300,642.03 in Q1 2023, showing an increase of 4.3%[20] - Net profit for Q1 2024 was ¥891,709,687.60, up from ¥859,198,906.19 in Q1 2023, reflecting a growth of 3.9%[20] Cash Flow and Assets - The net cash flow from operating activities increased by 21.26% to ¥1,135,769,256.97 from ¥936,665,805.67 in the same period last year[5] - The company's total liabilities decreased to CNY 4.823 billion from CNY 5.711 billion[17] - The cash and cash equivalents at the end of the period were CNY 7.578 billion, slightly down from CNY 7.584 billion[15] - The net cash flow from investment activities was -659,395,909.82 CNY, compared to -491,196,677.51 CNY in the previous year, indicating an increase in cash outflow[22] - The net cash flow from financing activities was -480,108,431.16 CNY, a significant increase from -83,894,379.73 CNY year-over-year[22] - The total cash and cash equivalents at the end of the period amounted to 7,535,306,650.71 CNY, down from 5,817,884,636.66 CNY in the previous year[22] - The company reported a decrease in cash and cash equivalents by 3,747,375.91 CNY during the quarter[22] Shareholder Information - The top shareholder, Changchun Chaoda Investment Group Co., Ltd., holds 18.85% of the shares, with a total of 76,256,454 shares[10] - The total number of common shareholders at the end of the reporting period was 130,749[10] Subsidiary Performance - Subsidiary Jin Sai Pharmaceutical generated revenue of CNY 2.470 billion and net profit of CNY 868 million[13] - Subsidiary Changchun High-tech Bio achieved revenue of CNY 270 million and net profit of CNY 61 million[14] Research and Development - Research and development expenses increased to ¥421,532,747.26, compared to ¥334,939,252.04 in the previous year, marking a rise of 25.8%[18] Operating Costs - Total operating costs for Q1 2024 were ¥2,102,994,280.55, up from ¥1,685,856,534.12, indicating a rise of 24.7%[18] - Sales expenses for Q1 2024 amounted to ¥927,736,758.74, compared to ¥841,041,858.55 in the same period last year, reflecting an increase of 10.3%[18] Equity and Return Metrics - Total assets at the end of the reporting period were ¥30,650,793,582.36, a decrease of 0.30% from ¥30,743,650,924.81 at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 3.45% to ¥22,836,867,782.84 from ¥22,074,934,790.14 at the end of the previous year[5] - The weighted average return on equity decreased to 3.83% from 4.63% in the previous year, a decline of 0.80%[5] - The equity attributable to shareholders increased to CNY 22.837 billion from CNY 22.075 billion[17] Audit Information - The company did not undergo an audit for the first quarter report[23]